Ocugen
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING1
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ArMaDa NCT06018558 |
P1/2 | Active, not recruiting | Geographic Atrophy | 60 | 2026-02-03 (-2 mo) |
| GARDian3 NCT05956626 |
P2/3 | Active, not recruiting | Stargardt Disease | 51 | 2026-09-28 (+11 mo) |
| liMeliGhT NCT06388200 |
P3 | Active, not recruiting | Retinitis Pigmentosa | 140 | 2027-02-12 (+19 mo) |
| OCU400 Low Dose NCT05203939 |
P1/2 | Active, not recruiting | Retinitis Pigmentosa; Leber Congenital Amaurosis | 22 | 2027-03 (+47 mo) |
| OCU410 NCT07770828 |
P3 | Recruiting | Dry Age-related Macular Degeneration | 237 | 2028-07-30 |